Nanox.AI vs Riverain Technologies
Both work on chest and body computed tomography and they answer different questions. Nanox mines scans taken for unrelated reasons, surfacing coronary calcium and vertebral fractures nobody ordered the scan to look for, with a clearance portfolio built over years and a listed parent behind it. Riverain suppresses the vessels so nodules that vasculature was hiding become visible, which changes what the radiologist sees rather than adding a list of what the model found. For a lung programme Riverain is aimed at the actual reason nodules get missed. For a population health programme Nanox is finding disease nobody was looking for, and generating a follow up obligation the health system pays for, which should be priced alongside the licence.
- Its strategy is opportunistic population health, mining scans taken for other reasons to surface findings including vertebral fractures and coronary calcium.
- A deep clearance portfolio built over years across several anatomical findings, with a listed parent whose filings describe the business.
- For a population health programme, finding disease nobody was looking for is the entire proposition.
- Vessel suppression addresses a specific reason nodules are missed rather than adding another findings list.
- Long established thoracic focus means the products have been in clinical use across several generations of scanner and protocol change.
- For a lung nodule programme, changing what the reader sees is a different intervention from flagging what the model found.
Side by Side
| Axis | N Nanox.AI |
R Riverain Technologies |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Opportunistic detection creates a duty to act whose cost falls on the health system rather than the vendor, since surfaced findings generate follow up imaging, patient notification and an incidental finding pathway, and that should be priced alongside the licence. Nanox publishes no health privacy commitment, data governance framework or subgroup analysis for a product designed to run across whole populations. Neither publishes pricing, and neither publishes performance on the scanner mix and protocols a given department actually uses.